Premier Alternatives

AbogenBio

Suzhou, China · Founded 2019 · Privately Held (backing)

Developer of mRNA based therapeutics focused on advancing clinical stage RNA medicines with a mission to revolutionise the future of health and life. AbogenBio is based in Suzhou, China and was founded in 2019. Its last reported valuation was $3.7 billion in Nov 2021. It has raised $1.1 billion.

Last reported valuation
$3.7B
Oct 2026
Priced at
—
Total raised
$1.1B
Last round
—

AbogenBio key facts

as of Oct 2026
  • Developer of mRNA based therapeutics focused on advancing clinical stage RNA medicines with a mission to revolutionise the future of health and life.
  • AbogenBio is valued at approximately $3.7B as of Oct 2026 (last reported valuation).
  • It has raised $1.1B; the latest was Later Stage VC in Jul 2025.
  • Notable investors include Coatue Management, SoftBank Investment Advisers, Qiming Venture Partners, Temasek Holdings, Oriental Fortune Capital — 44 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$3.7B

AbogenBio's last reported valuation, Nov 2021. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of AbogenBio with a free account
  • ·The complete investor list: 44 names
  • ·Watch AbogenBio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

AbogenBio funding rounds

No rounds on record

No funding rounds for AbogenBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

AbogenBio valuation

AbogenBio's last reported valuation was $3.7 billion in Nov 2021. No priced round, secondary trade or fund mark has surfaced since.

AbogenBio investors

44 investors are on record for AbogenBio, including Coatue Management, SoftBank Investment Advisers, Qiming Venture Partners and Temasek Holdings. By type, the record holds 8 venture capital firms and 2 private equity firms.

About AbogenBio

Developer of mRNA based therapeutics focused on advancing clinical stage RNA medicines with a mission to revolutionise the future of health and life. The company's offerings include mRNA LNP platforms, mRNA modified therapeutics, delivery technology systems, immuno oncology candidates, autoimmune disease therapies and infectious disease vaccine programs, enabling the creation of scalable, next generation RNA medicines that expand treatment possibilities across multiple therapeutic areas.

Sector
Healthcare
HQ
Suzhou, China
Founded
2019
Employees
8
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.